A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2029

Conditions

CancerSolid Tumor

Interventions

BIOLOGICAL

Personalized Synthetic Long Peptide Vaccine

Trial Locations (5)

Virginia Cancer Specialists, Fairfax

Mount Sinai Medical Center, Miami Beach

St. Louis Cancer Care, Bridgeton

Precision NextGen Oncology & Research Center, Beverly Hills

Quest Clinical Research, San Francisco

All Listed Sponsors

lead

Jaime Leandro Foundation for Therapeutic Cancer Vaccines

OTHER